Y Intercept Hong Kong Ltd Acquires 70,326 Shares of Organon & Co. $OGN

Y Intercept Hong Kong Ltd grew its holdings in shares of Organon & Co. (NYSE:OGN) by 17.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 476,488 shares of the company’s stock after acquiring an additional 70,326 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Organon & Co. were worth $2,854,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OGN. AQR Capital Management LLC raised its holdings in Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. UBS Group AG increased its position in shares of Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after buying an additional 1,527,492 shares during the period. Private Management Group Inc. increased its position in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after buying an additional 1,204,979 shares during the period. Balyasny Asset Management L.P. raised its stake in Organon & Co. by 102.1% in the third quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after buying an additional 1,131,941 shares in the last quarter. Finally, Gotham Asset Management LLC lifted its holdings in Organon & Co. by 37.2% in the third quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock worth $39,657,000 after buying an additional 1,007,691 shares during the period. Institutional investors own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Weiss Ratings upgraded Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. BNP Paribas Exane restated a “neutral” rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and upped their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Price Performance

Shares of OGN opened at $13.51 on Wednesday. The firm has a fifty day simple moving average of $13.41 and a two-hundred day simple moving average of $9.64. The firm has a market cap of $3.55 billion, a PE ratio of 14.52, a P/E/G ratio of 1.26 and a beta of 1.54. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.60.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the business posted $1.02 EPS. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, equities analysts anticipate that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Monday, May 11th were given a dividend of $0.02 per share. The ex-dividend date was Monday, May 11th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is currently 8.60%.

Insider Transactions at Organon & Co.

In related news, SVP Lynette Holzbaur bought 26,448 shares of the stock in a transaction dated Wednesday, May 6th. The shares were purchased at an average price of $13.35 per share, with a total value of $353,080.80. Following the completion of the acquisition, the senior vice president owned 52,851 shares of the company’s stock, valued at $705,560.85. This represents a 100.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.62% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.